SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Sick Visit — Frédéric Chopin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Frédéric Chopin |
|---|
| Date of birth | 1810-03-01 |
|---|
| Identifiers | MRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845 |
|---|
| Document date | 1838-06-09 |
|---|
| Author | Matthias Lindqvist, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Chief Complaint
Sore throat, runny nose, and cough for three days during tuberculosis treatment. [S]
History of Present Illness
Mr. Chopin is a 28-year-old pianist in the fourth week of the continuation phase of rifapentine, moxifloxacin, and isoniazid for cavitary pulmonary tuberculosis, given by video-observed therapy. Three days ago he developed a scratchy throat and a runny, blocked nose, then a mild dry cough; two of his students had colds last week. His temperature at home has been up to 37.7 °C. He is frightened that the tuberculosis is coming back, because the cough is the first he has had in a month. He has no blood in his sputum, no night sweats, and no weight loss; he has gained 1.6 kg since the end of the intensive phase. He has taken every dose on his video calls. He has not taken anything for the cold yet and asked whether zinc lozenges or an antibiotic would help. He has no tendon pain, tingling, rash, yellowing, or dark urine. [S]
| Element | Detail |
|---|
| Onset | Three days ago |
| Location | Throat and nose, with a mild cough |
| Duration | Three days |
| Character | Scratchy throat, runny and blocked nose, dry cough |
| Severity | Mild; teaching with difficulty |
| Timing | Week 12 of 17 of tuberculosis treatment |
| Context | Students with colds last week |
| Modifying factors | Nothing taken yet; no doses missed |
| Associated signs and symptoms | Temperature up to 37.7 °C; no hemoptysis, night sweats, or weight loss |
Review of Systems
| System | Result | Finding |
|---|
| Constitutional | Positive | Low-grade temperature; no night sweats or weight loss |
| Ears, nose, mouth, and throat | Positive | Sore throat, runny and blocked nose; no ear pain |
| Respiratory | Positive | Mild dry cough for two days; no blood, breathlessness, or chest pain |
| Gastrointestinal | Negative | No nausea, abdominal pain, or jaundice |
| Musculoskeletal | Negative | No tendon or joint pain |
| Neurological | Negative | No numbness or tingling in his fingers or feet |
6 systems reviewed. [S]
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 1838-03-20 to 1838-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 1838-06-09 | Body height | 170 | cm | S |
| 1838-06-09 | Body weight | 53.6 | kg | S |
| 1838-06-09 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 1838-06-09 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1838-06-09 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1838-06-09 | Heart rate | 88 | /min | S |
| 1838-06-09 | Respiratory rate | 16 | /min | S |
| 1838-06-09 | Body temperature | 37.6 | Cel | S |
| 1838-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Physical Exam
Vital signs recorded on 1838-06-09; see the Vital Signs section. [S]
| System | Finding |
|---|
| General | Tired but well; weight 53.6 kg; temperature 37.6 °C; masked in the waiting room |
| Ears, nose, and throat | Nasal mucosa red and swollen with clear discharge; pharynx mildly red without exudate; ear drums normal |
| Neck | Small, soft, tender anterior lymph nodes |
| Respiratory | Clear, with no crackles or bronchial breathing over the right upper zone |
| Skin | No rash or jaundice |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed |
R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed |
A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | active | confirmed |
E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
| Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolved | resolved | confirmed |
J06.9 | S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness. |
Assessment and Plan
- Acute viral upper respiratory infection (J06.9). A cold caught from his students: a short illness with a sore throat and runny nose before the cough, a normal chest examination, and continued weight gain. This is not tuberculosis treatment failure, which would bring back cough with sputum, night sweats, weight loss, or hemoptysis over weeks, and his April cultures were negative. Antibiotics would not help. Zinc lozenges and mineral-containing cold remedies bind moxifloxacin and lower its absorption, and an antibiotic such as azithromycin would add to the QT effect of moxifloxacin. [S]
- Fluids, honey, rest, and saline nose spray; acetaminophen for throat pain or fever.
- No zinc lozenges or mineral-containing remedies within four hours before or eight hours after his morning dose; no antibiotic.
- Keep taking every dose on the video calls.
- Wear a mask while coughing and move lessons online for a few days, as anyone with a cold would.
- Return for a cough lasting beyond two to three weeks, blood in the sputum, night sweats, or weight loss, for sputum smear and culture.
- Pulmonary tuberculosis, continuation phase (A15.0). Responding well: symptoms of tuberculosis gone, weight rising, every dose observed. No tendon pain, tingling, or signs of liver injury. [S]
- Continue rifapentine, moxifloxacin, isoniazid, and pyridoxine to the 119th dose.
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention (2016)
Follow-up: Message if the cold is not better in a week. End-of-treatment visit after the last dose in July. Next scheduled visit 1838-07-21: end-of-treatment review after 119 doses. [S]